Disparities in Melanoma Incidence Between Sex and Age Populations in the United States Between 2001 and 2021
Main Article Content
Keywords
Melanoma, Incidence, Sex-specific, Age-specific, Trends
Abstract
Introduction: This population-based study aimed to determine the incidence rates of melanoma in the U.S. and specifically assess the sex- and age-specific differences among different populations. Previous studies showed an increase in incidence of melanoma, but no clear sex-specific rates.
Methods: The United States Cancer Statistics (USCS) database, which covers 98% of the U.S. population, was used to identify patients with melanoma between 2001-2021. Melanoma incidence rates per 100,000 population were age-adjusted and calculated using SERR*Stat software and were stratified by sex and age into older and younger patients (age cutoff of 40 years). Time-trends (reported as annual percentage change “APC” and average APC “AAPC”) were estimated using Joinpoint regression via the modified weighted Bayesian Information Criteria method. Sex-specific trends were compared using the tests of parallelism and identicalness (P<0.05).
Results: Overall, there were 1,480,740 patients diagnosed with melanoma in the U.S. between 2001-2021. Melanoma incidence rates increased in men (AAPC=1.15; P<0.01) and women (AAPC=1.30; P<0.01). In older patients, incidence rates increased in men (AAPC=1.47; P<0.01) and women (AAPC=1.86; P<0.01) without significance (P=0.35).
However, in younger patients (149,020 patients), melanoma incidence decreased in younger men (AAPC= -2.19%; P<0.01), but not in younger women (AAPC= - 0.54%; P<0.19). Sex-specific difference was significant with absolute AAPC value of 1.65 (P<0.01) and non-parallel non-identical trends (P-values<0.01).
Discussion: In summary, there was a decline in melanoma cases among men but no change among women with significant differences. This sparks the need for additional research to delve into the potential causes of these sex-based differences in cases of melanoma.
References
2. Guy GP, Ekwueme DU, Tangka FK, Richardson LC. Melanoma Treatment Costs. Am J Prev Med. 2012;43(5):537-545. doi:10.1016/j.amepre.2012.07.031
3. Dzwierzynski WW. Melanoma Risk Factors and Prevention. Clin Plast Surg. 2021;48(4):543-550. doi:10.1016/j.cps.2021.05.001
4. Kim HJ, Chen HS, Midthune D, et al. Data-driven choice of a model selection method in joinpoint regression. J Appl Stat. 2023;50(9):1992-2013. doi:10.1080/02664763.2022.2063265
5. Buja A, Rugge M, Damiani G, et al. Sex Differences in Cutaneous Melanoma: Incidence, Clinicopathological Profile, Survival, and Costs. J Womens Health. 2022;31(7):1012-1019. doi:10.1089/jwh.2021.0223
6. Bellenghi M, Puglisi R, Pontecorvi G, De Feo A, Carè A, Mattia G. Sex and Gender Disparities in Melanoma. Cancers (Basel). 2020;12(7):1819. doi:10.3390/cancers12071819
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.